作者：徐泽锋ruxolitinibcombinedprednisonethalidomideapilotstudy
摘要：Objective To evaluate the efficacy and tolerabilityof ruxolitinib combined with prednisone,thalidomide anddanazol for treatment of in myelofibrosis (MF). MethodsPatients of MF according to the WHO 2016 criteria,received ruxolitinib (RUX) combined with prednisone,thalidomide and danazol (PTD). The response,changesof blood counts and adverse events were evaluated. ResultsSix PMF and one post-ET MF patients were enrolled.Four patients presented JAK2V617F mutation,one CALR mutation,one MPL mutation,one triple-negative .Responses per IWG-MRT criteria were clinical improvementin 5 patients,stable disease in 2 ones,spleenresponse in 6 ones. All of 7 patients were symptomaticresponses,four patients achieved at least 50% improvementfrom baseline on MPN-SAF TSS. Three patients initiallywere treated with RUX alone,all of 3 patients experiencedtreatment-associated anemia and thrombocytopenia.
注：因版权方要求，不能公开全文，如需全文，请咨询杂志社
